KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Change in Receivables: 2010-2025

Historic Change in Receivables for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to $71.6 million.

  • Emergent BioSolutions' Change in Receivables rose 187.00% to $71.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $103.5 million, marking a year-over-year increase of 215.51%. This contributed to the annual value of $24.4 million for FY2024, which is 12.96% up from last year.
  • Latest data reveals that Emergent BioSolutions reported Change in Receivables of $71.6 million as of Q3 2025, which was up 160.42% from -$118.5 million recorded in Q2 2025.
  • Emergent BioSolutions' Change in Receivables' 5-year high stood at $132.4 million during Q2 2023, with a 5-year trough of -$118.5 million in Q2 2025.
  • For the 3-year period, Emergent BioSolutions' Change in Receivables averaged around $6.6 million, with its median value being -$2.6 million (2023).
  • Within the past 5 years, the most significant YoY rise in Emergent BioSolutions' Change in Receivables was 3,410.00% (2023), while the steepest drop was 569.08% (2023).
  • Emergent BioSolutions' Change in Receivables (Quarterly) stood at -$98.5 million in 2021, then skyrocketed by 63.86% to -$35.6 million in 2022, then decreased by 3.65% to -$36.9 million in 2023, then soared by 308.94% to $77.1 million in 2024, then soared by 187.00% to $71.6 million in 2025.
  • Its Change in Receivables stands at $71.6 million for Q3 2025, versus -$118.5 million for Q2 2025 and $73.3 million for Q1 2025.